Download news release - Foundation Medicine

NEWS RELEASE
FOR IMMEDIATE RELEASE
Foundation Medicine to Present Cancer Genomic Research and Clinical Findings at the
AACR Annual Meeting 2013
CAMBRIDGE, Mass., March 28, 2013 - Foundation Medicine, Inc., a molecular information
company that brings comprehensive cancer genomic diagnostic testing and analysis to routine
clinical care, today announced the company’s participation in multiple sessions and
presentations at the American Association for Cancer Research (AACR) Annual Meeting 2013
taking place April 6-10, 2013 in Washington, D.C.
“The clinical benefit of comprehensive genomic profiling in cancer care is becoming
increasingly clear as Foundation Medicine continues to present new clinical and research
findings,” said Vincent Miller, M.D., senior vice president, clinical development, Foundation
Medicine. “The collaborative studies and sessions at AACR should help advance the
application of genomics and next-generation sequencing in clinical practice, and it is gratifying
to see such encouraging progress.”
The schedule for Foundation Medicine’s presentations and posters is as follows:
Date & Time: Saturday, April 6, 2013 from 10:15 to 10:40 a.m. ET
Title: Clinical application of genome profiling in lung cancer
Session: Future directions in personalized medicine for lung cancer
Type: Educational Session
Location: Room 143, Washington Convention Center
Presenter: Vincent Miller, M.D., senior vice president, clinical development, Foundation
Medicine
Date & Time: Sunday, April 7, 2013 from 1:00 to 5:00 p.m. ET
Title: Differences in genomic alterations revealed by sequencing of 182 genes in recurrent
ovarian cancer specimens compared to TCGA analysis: rearrangements in PTCH1 and FLT3;
high frequency of RAS pathway alteration
Abstract Number: 58
Session: Molecular Diagnostics
Type: Poster Session
Location: Hall A-C, Poster Section 3
Presenter: Deborah A. Zajchowski, Ph.D., scientific director, The Clearity Foundation
(research in collaboration with Foundation Medicine)
Date & Time: Monday, April 8, 2013 from 1:00 to 5:00 p.m. ET
Title: Identification of a novel genetic abnormality, the amplification of rictor (rapamycininsensitive companion of mTOR), in a patient with non-small cell lung cancer
Abstract Number: 2033
Session: Combination Therapies and Novel Therapeutic Approaches
Type: Poster Session
Location: Hall A-C, Poster Section 36
Presenter: Haiying Cheng, M.D., assistant professor, department of medicine, Albert Einstein
College of Medicine of Yeshiva University (research in collaboration with Columbia
University and Foundation Medicine)
Date & Time: Monday, April 8, 2013 from 1:00 to 5:00 p.m. ET
Title: Next generation sequencing demonstrates multiple gene amplifications and mutations in
3 patients with estrogen receptor-positive breast cancer with responses to treatment with
combination aromatase and PI3K/AKT/mTOR pathway inhibition
Abstract Number: 1209
Session: Molecular Classification of Tumors
Type: Poster session
Location: Hall A-C, Poster Section 3
Presenter: Ralph Zinner, M.D., associate professor, Department of Investigational Cancer
Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer
Center (research in collaboration with Foundation Medicine)
Date & Time: Monday, April 8, 2013 from 3:00 to 5:00 p.m. ET
Title: Bringing next generation sequencing (NGS) to the clinic: Analytical validation of a
comprehensive NGS-based cancer gene test
Abstract Number: 2279
Session: Identification of New Targets and Pathways in Cancer: Translating Basic Discoveries
into the Clinic
Type: Minisymposium
Location: Room 207, Washington Convention Center
Presenter: Roman Yelensky, director, clinical genomic analysis, Foundation Medicine
Date & Time: Tuesday, April 9, 2013 from 8:15 to 10:15 a.m. ET
Session: Regulatory Considerations for Integrative Biomarker Development Using Whole
Genome Technologies
Type: Regulatory Science and Policy Session
Location: Room 144, Washington Convention Center
Presenter: Vincent Miller, M.D., senior vice president, clinical development, Foundation
Medicine
Date & Time: Tuesday, April 9, 2013 from 1:00 to 5:00 p.m. ET
Title: A dose-escalation study of anastrozole and everolimus in patients with advanced
gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations
in the PI3K/AKT/mTOR pathway
Abstract Number: 3514
Session: New Agents Targeting Signaling Pathways 2: Clinical Trials and Other Patient-Based
Studies
Type: Poster Session
Location: Hall A-C, Poster Section 3
Presenter: Jennifer J. Wheler, assistant professor, Department of Investigational Cancer
Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer
Center (research in collaboration with Foundation Medicine)
Date & Time: Tuesday, April 9, 2013 from 5:00 to 6:00 p.m. ET
Session: Next Generation Sequencing in the Clinic
Type: Forum
Location: Room 207, Washington Convention Center
Presenter: Vincent Miller, M.D., senior vice president, clinical development, Foundation
Medicine
About Foundation Medicine
Foundation Medicine® is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding of the genomic changes
that contribute to each patient’s unique cancer. The company’s initial clinical assay,
FoundationOneTM, is a fully informative genomic profile to identify a patient’s individual
molecular alterations and match them with relevant targeted therapies and clinical trials.
Foundation Medicine’s molecular information platform aims to improve day-to-day care for
patients by serving the needs of clinicians, academic researchers and drug developers to help
advance the science of molecular medicine in cancer. For more information, please visit
www.FoundationMedicine.com
or
follow
Foundation
Medicine
on
Twitter
(@FoundationATCG).
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of Foundation Medicine, Inc.
Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
###